[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553654":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":41,"collaborators":43,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":19,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":19,"enrollmentInfo":55,"targetDuration":19,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":19,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Instituto de Investigación Hospital Universitario La Paz","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Allogeneic adipose tissue-derived mesenchymal stem cells","EXPERIMENTAL","Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an \"advanced therapy medicinal product\" according to European regulation (Regulation (EC) No 1394\u002F2007).",[13],"Drug: Allogeneic adipose tissue-derived mesenchymal stem cells",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Investigational medicinal product: Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an \"advanced therapy medicinal product\" under European regulation (Article 2(1) of Regulation (EC) No 1394\u002F2007 of the European Parliament and the Council of November 13 th 2007 about advanced therapy medicinal products and amending Directive 2001\u002F83\u002FEC and Regulation (EC) No 726\u002F2004).\n\nAdministration form: Local injection by means of a catheter placed inside the previously excluded aneurysmal sac.\n\nAdministration dose: 1x10000000 cells\u002Fkg patient weight.\n\nAdministration guidelines: single infusion on the endovascular day AAA intervention.",[9],null,[21],{"facility":22,"status":23,"city":24,"state":19,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Hospital Universitario La Paz","RECRUITING","Madrid","28046","Spain","ES",{"type":29,"coordinates":30},"Point",[31,32],-3.70256,40.4165,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Luis Riera del Moral, Doctor of Medicine","CONTACT","917277000","441189","luis.riera@salud.madrid.org",{"type":42,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[44],{"name":45,"class":46},"Grupo Dermatologico Y Estetico Pedro Jaen S.A.","UNKNOWN","100553654","phase-2-abdominal-aortic-aneurysm-stabilization-with-truncal-cells-controlled-clinical-trial-with-historical-cohorts-100553654",false,"NCT06488898","Abdominal Aortic Aneurysm Stabilization With Truncal Cells: Controlled Clinical Trial With Historical Cohorts","Inclusion Criteria:\n\n1. Subjects with AAA greater than 5 cm diameter with endovascular treatment indication, analyzed by aortic AngioCT.\n2. Subjects ≥ 18 years at the time of inclusion.\n3. Subjects with a good infrarenal neck for a standard device placement, neither fenestrated nor branched.\n4. Patients with an estimated life expectancy greater than 2 years at the time of inclusion.\n5. Women with childbearing capacity must have a negative pregnancy test at the time of inclusion and must agree to use highly effective contraceptive methods (diaphragms plus spermicide or male condom plus spermicide, oral contraceptive combined with a second method contraceptive implant, injectable contraceptive, permanent intrauterine device, sexual abstinence or partner with vasectomy) during their study participation.\n6. The patient must be able to attend all study visits and comply with all study procedures.\n\nExclusion Criteria:\n\n1. Patients with unresolved neoplasia history or hematologic disease.\n2. Patients with uncontrolled arterial hypertension (≥180\u002F110) at the time of inclusion.\n3. Patients with severe heart failure (New York Heart Association \\[NYHA\\] IV) or ejection fraction \\\u003C20%.\n4. Patients with malignant ventricular arrhythmias\n5. Patients with deep vein thrombosis the last three months\n6. Patient with active sepsis at the time of inclusion\n7. Patients with acute myocardial infarction or stroke in the previous month\n8. Any type of medical or psychiatric illness that, in investigator opinion, could be a reason for exclusion from the study.\n9. Patient with major surgery or severe craniocerebral trauma in the 3 months prior to inclusion in the study.\n10. Administration of any investigational drug at the time of inclusion or in the 3 months prior\n11. Infants or pregnant women\n12. Transplanted patients.","ALL","18 Years",{"count":56,"type":57},8,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","Phase IIa, single-center clinical trial compared with historical cohorts to evaluate the preliminary safety and efficacy of an allogeneic adipose tissue-derived mesenchymal stem cells infusion in an aneurysmal sac for the treatment of AAA.",[63],"Aortic Aneurysm, Abdominal","2024-07-04",{"date":66,"type":67},"2024-07-08","ACTUAL",{"date":69,"type":67},"2024-06-13",{"date":71,"type":57},"2025-12-31",{"name":5,"class":6},1]